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ADRENOCORTICAL CARCINOMA,
A STRESSFUL DIAGNOSIS
Shabnam Khoie, DO; Dmitriy Scherbak, DO; HCA HealthONE/Rocky Vista University- Sky Ridge Medical Center
Introduction

Images

Discussion

Adrenocortical carcinoma (ACC) is a rare and biologically aggressive
malignancy. The incidence of ACC is between 0.7-2 cases per
1
million, accounting for 0.05-2% of all malignant tumors .

Approximately 80% of patients with adrenal incidentalomas have a
non-functional adenoma; less than 5% of patients with adrenal
incidentalomas will have ACC3.

Cortisol-producing ACC is the most common type, occurring in
30-40% of all ACCs1.

Patients with adrenal incidentalomas should undergo evaluation for
signs and symptoms of hypercortisolism, hyperaldosteronism,
presence of pheochromocytoma, or a malignant tumor3. Evaluation
for hypercortisolism includes the measurement of serum
dehydroepiandrosterone sulfate and low-dose dexamethasone
suppression testing4. If the patient is hypertensive, evaluation for
hyperaldosteronism should include the measurement of plasma
aldosterone and plasma renin4.

Patients classically present with features of elevated cortisol:
2
refractory hypertension, glucose intolerance, and central obesity .
We present a case of a 75-year-old male with a cortisol-secreting
variant of adrenocortical carcinoma.

Case Report

Image B: Initial, coronal
view of the adrenal mass

Image A: Initial, transverse
view of the adrenal mass

Initial Biochemical Work Up
Test

Result

Normal Range

A 75-year-old male, with a prior medical history significant for
hypertension, type two diabetes, and severe, untreated obstructive
sleep apnea, presented to the emergency department with a blood
pressure of 259/123 and respiratory distress.

Urine Total Catecholamines

<60 mcg/g

9-74 mcg/g

Urine Epinephrine

<20 mcg/g

2-16 mcg/g

Urine Norepinephrine

<40 mcg/g

7-65 mcg/g

Urine Total Metanephrines

505 mcg/24h

149-603 mcg/24h

Computerized tomography angiography (CTA) revealed a
heterogeneous slightly lobulated, macroscopic fat-containing mass
in the left adrenal gland, measuring up to 4 cm (image A and B).
Initial biochemical work up was unremarkable for a hypertensive
etiology.

Urine Fractionated Metanephrines 56 mcg/g

For adrenal incidentalomas measuring >4 cm, open adrenalectomy
is gold standard of treatment. For those <4 cm, repeat imaging
should be performed at 3 and 6 months, and then annual for 1-2
years. Biochemical follow up should be performed annual for up to
five years. Interval enlargement of more than 1 cm warrants
consideration of resection3.

21-153 mcg/g

Urine Dopamine

106 mcg/g

40-390 mcg/g

Serum Aldosterone

11 ng/dL

< or = 28 ng/dL

Serum Renin Activity

0.47 ng/mL/h

0.25-5.82 ng/mL/h

Initial work up did not include dehydroepiandrosterone sulfate testing.

A year later, imaging revealed the same left adrenal mass, now
measuring 7.1 cm x 5.8 cm with extensive mediastinal and hilar
lymphadenopathy (image C and D).

This case illustrates the importance of longitudinal radiographic
monitoring and frequent, complete biochemical evaluation of an
adrenal incidentaloma. Although the patient’s biochemical evaluation
was unremarkable at the time of incidentaloma discovery, the rate of
mass growth revealed on imaging should highlight the importance of
clinical suspicion of an adrenocortical carcinoma.
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Left adrenal mass core biopsies revealed benign adrenocortical
neoplasm, favoring adenoma, negative for metastatic carcinoma.
Hospital course was complicated by bacteremia, septic shock
requiring stress-dose steroids, and respiratory failure.
Subcarinal lymph node fine needle aspiration revealed malignant
cells, consistent with metastatic adrenocortical carcinoma.
Further work up was deferred, as the patient pursued hospice.

Image C: Transverse view
of the adrenal mass during
a prone, CT-guided adrenal
biopsy

Image D: Coronal view of
the adrenal mass during a
CT-guided adrenal biopsy
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